Silence Therapeutics (SLN) Total Non-Current Liabilities (2019 - 2023)

Silence Therapeutics has reported Total Non-Current Liabilities for 5 years, with the latest figure at $73.2 million in Q4 2023.

• Quarterly Total Non-Current Liabilities fell 1.65% year-over-year to $73.2 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $73.2 million (down 1.65% YoY) and the FY2023 annual result came in at $73.2 million, down 6.79% from the prior year.
• Total Non-Current Liabilities slipped to $73.2 million in Q4 2023 per SLN's latest filing, from $74.5 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $97.7 million in Q4 2021 and troughed at $19.9 million in Q4 2019.
• A 5-year average of $66.6 million and a median of $73.2 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2020 and 2022: Total Non-Current Liabilities soared 239.82% in 2020, then slipped 23.81% in 2022.
• Over 5 years, Total Non-Current Liabilities stood at $19.9 million in 2019, then jumped by 239.82% to $67.8 million in 2020, then soared by 44.17% to $97.7 million in 2021, then declined by 23.81% to $74.5 million in 2022, then declined by 1.65% to $73.2 million in 2023.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $73.2 million, $74.5 million, and $97.7 million for Q4 2023, Q4 2022, and Q4 2021 respectively.